The Emmes Company, LLC
The Emmes Company, LLC
Explore linked clinical trials.17 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combatting HIV Or Other STIs Early (CHOOSE) | Disease Attributes, Genital Diseases, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, infectious disease, sexually transmitted disease | Recruiting | Not applicable | 2026-10-09 | NCT07510048 | |
| Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services | HIV; PrEP; PrEP Adherence | Recruiting | Not applicable | 2026-10-09 | NCT07438041 | |
| Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses | Chemically-Induced Disorders, Hemic and Lymphatic Diseases, Narcotic-Related Disorders, Neoplasms by Histologic Type, Opioid Use Disorder, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, opiate dependence, psychiatric disorder, substance-related disorder | Recruiting | Not applicable | 2026-10-01 | NCT07631598 | |
| Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) | Chemically-Induced Disorders, Narcotic-Related Disorders, opiate dependence, psychiatric disorder, substance-related disorder | Active, not recruiting | Phase 2 | 2026-10-01 | NCT04464980 | |
| Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons | Chemically-Induced Disorders, Narcotic-Related Disorders, Opioid Use Disorder, opiate dependence, psychiatric disorder, substance-related disorder | Not yet recruiting | Phase 2 | 2026-09-28 | NCT05382091 | |
| Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment. | Chemically-Induced Disorders, Narcotic-Related Disorders, Opioid Use Disorder, opiate dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 4 | 2026-09-14 | NCT06323824 | |
| EMS-Initiated Buprenorphine | Chemically-Induced Disorders, Narcotic-Related Disorders, Opioid Use Disorder, opiate dependence, psychiatric disorder, substance-related disorder | Recruiting | Not stated | 2026-08-27 | NCT07475728 | |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | Abnormalities, Multiple, Arrhythmias, Cardiac, COVID-19, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Coronaviridae Infections, Down syndrome, Dyssomnias, Edema, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Hemic and Lymphatic Diseases, Hemorrhage, Infant, Newborn, Diseases, Infant, Premature, Diseases, Infections, Inflammation, Kawasaki disease, Lung Injury, Menorrhagia, Menstruation Disturbances, Neurobehavioral Manifestations, Neurologic Manifestations, Nidovirales infectious disease, Nutritional and Metabolic Diseases, Orthocoronavirinae infectious disease, Pain, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, Signs and Symptoms, Skin and Connective Tissue Diseases, Sleep Disorders, Intrinsic, Suppuration, Urogenital Diseases, Uterine Hemorrhage, Ventilator-Induced Lung Injury, Water-Electrolyte Imbalance, adrenal gland disorder, adrenal gland hyperfunction, adrenocortical insufficiency, attention deficit hyperactivity disorder, inattentive type, blood coagulation disease, bronchopulmonary dysplasia, cardiovascular disorder, cellulitis, chromosomal disorder, coagulation protein disease, connective tissue disorder, endocrine system disorder, female reproductive system disorder, heart disorder, heart failure, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, hyperaldosteronism, hyperphosphatemia, hypertensive disorder, inherited blood coagulation disorder, insomnia, intellectual disability, lung disorder, lymphatic system disorder, metabolic disease, nervous system disorder, neurodevelopmental disorder, oppositional defiant disorder, pediatric multisystem inflammatory disease, COVID-19 related, phosphorus metabolism disease, pneumonia, potassium deficiency disease, primary aldosteronism, psychiatric disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder, respiratory tract infectious disorder, skin disorder, skin disorder caused by infection, skin infection, skin vascular disease, sleep-wake disorder, uterine disorder, vascular disorder, vascular hemostatic disease, vasculitis, viral infectious disease, viral pneumonia | Recruiting | Not stated | 2026-08-21 | NCT04278404 | |
| Anesthetics and Analgesics in Children | Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Recruiting | Not stated | 2026-08-05 | NCT03427736 | |
| Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants | Breastfed Infants of Mothers on Select DOI; Lactating Women on Select DOI | Recruiting | Not stated | 2026-07-29 | NCT03511118 | |
| Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urinary Incontinence, Urination Disorders, Urogenital Diseases, Urological Manifestations, overactive bladder, urinary bladder disorder, urinary system disorder | Not yet recruiting | Phase 4 | 2026-06-17 | NCT06769854 | |
| A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, plasmablastic lymphoma | Recruiting | Early phase 1 | 2026-06-01 | NCT04139304 | |
| Standard Versus High Dose ED-Initiated Buprenorphine Induction | Chemically-Induced Disorders, Narcotic-Related Disorders, Opioid Use Disorder, opiate dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 3 | 2026-05-28 | NCT06494904 | |
| Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF) | Crohn ileitis, Digestive System Diseases, Ileal Diseases, digestive system disorder, enteritis, gastroenteritis, intestinal disorder, pouchitis | Recruiting | Phase 1 / Phase 2 | 2026-05-28 | NCT05938465 | |
| EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy | Chemically-Induced Disorders, Hemic and Lymphatic Diseases, Narcotic-Related Disorders, Neoplasms by Histologic Type, Substance Use Disorders, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, opiate dependence, psychiatric disorder, substance-related disorder | Active, not recruiting | Not applicable | 2026-04-23 | NCT04921787 | |
| Integrating MOUD in Nonmedical Community Settings (Better Together) | Chemically-Induced Disorders, Narcotic-Related Disorders, Opioid Use Disorder, opiate dependence, psychiatric disorder, substance-related disorder | Not yet recruiting | Not applicable | 2025-12-03 | NCT06416020 | |
| Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients | Chemically-Induced Disorders, Substance Use Disorders, psychiatric disorder, substance-related disorder | Active, not recruiting | Not applicable | 2025-10-21 | NCT05688423 |